752174-62-2

Usage

Uses

Used in Organic Synthesis:
(2R,4S)-ethyl 5-([1,1'-biphenyl]-4-yl)-4-aMino-2-Methylpentanoate is used as a building block in organic synthesis for its unique structural features, including the biphenyl and amino groups, which can be utilized in the creation of more complex organic molecules.
Used in Pharmaceutical Development:
In the pharmaceutical industry, (2R,4S)-ethyl 5-([1,1'-biphenyl]-4-yl)-4-aMino-2-Methylpentanoate is used as a potential active pharmaceutical ingredient or as an intermediate in the synthesis of drug candidates, leveraging its chiral nature and functional groups for medicinal chemistry applications.
Used as a Research Reagent:
(2R,4S)-ethyl 5-([1,1'-biphenyl]-4-yl)-4-aMino-2-Methylpentanoate serves as a research reagent in academic and industrial laboratories, where it may be employed to study the effects of stereochemistry on chemical reactions and to explore its potential in various chemical and biological assays.
Further investigation is necessary to fully understand the properties and potential uses of (2R,4S)-ethyl 5-([1,1'-biphenyl]-4-yl)-4-aMino-2-Methylpentanoate, as its specific configuration and functional groups may offer unique advantages in various applications.

Upstream product

• 1012341-50-2 (2R,4S)-5-[(1,1‘-biphenyl)-4-yl]-4-((tert-butoxycarbonyl)amino)-2-methylpentanoic acid 
• 64-17-5 ethanol 
• 1012341-48-8 (2E,4R)-5-{[1,1'-biphenyl]-4-yl}-4-{[(tert-butoxy)carbonyl]amino}-2-methylpent-2-enoic acid 
• 4676-51-1 (2R)-diethyl 2-methylsuccinate 
• 5728-52-9 (4-biphenylyl)acetic acid 
• 1039307-95-3 (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-amino-2-methylpentanoic acid 
• 1038924-71-8 (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-amino-2-methylpentanoic acid hydrochloride 
• 31603-77-7 4-biphenylacetonitrile 
• 100160-75-6 methyl 4-([1,1'-biphenyl]-4-yl)-3-oxobutyrate 
• 149709-56-8 methyl N-(tert-butoxycarbonyl)-O-[(trifluoromethyl)sulfonyl]-D-tyrosinate 
• 76757-90-9 N-(tert-butoxycarbonyl)-D-tyrosine methyl ester 

Downstream Products

• 1257265-89-6 6-amino-2-((1S,3R)-1-biphenyl-4-ylmethyl-3-carboxy-butylcarbamoyl)-pyrimidine-4-carboxylic acid 
• 1257265-90-9 4-amino-6-((1S,3R)-1-biphenyl-4-ylmethyl-3-carboxy-butylcarbamoyl)-pyrimidine-2-carboxylic acid 
• 149709-62-6 α-ethyl (αR,γS)-γ-<(3-carboxy-1-oxopropyl)amino>-α-methyl<1,1'-biphenyl>-4-pentanoate 
• 1639970-62-9 (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-(2,5-dioxopyrrol-1-yl)-2-methylpentanoic acid 
• 1038924-97-8 (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-(2,5-dioxopyrrol-1-yl)-2-methyl pentanoate 
• 1038924-70-7 (3R,5S)-5-({[1,1'-biphenyl]-4-yl}methyl)-3-methylpyrrolidin-2-one 

Relevant academic research and scientific papers

Preparation method and application of sacubitril intermediate

The invention discloses a preparation method and application of a sacubitril intermediate. The sacubitril intermediate disclosed by the invention is obtained by taking itaconic anhydride as a raw material, performing chiral reduction, esterification, selective hydrolysis and carboxyl activation, and finally conducting coupling with 4-biphenylacetic acid. The invention also provides a method for preparing sacubitril by using the sacubitril intermediate. The preparation method provided by the invention has the advantages of easily available raw materials, simple process, economy, environmental protection and the like, and is more suitable for industrial production compared with other routes.

Preparation method of sacubitril-valsartan compound and/or eutectic key intermediate sacubitril calcium

The invention relates to a preparation method of a sacubitril-valsartan compound and/or eutectic key intermediate sacubitril calcium. The provided preparation method of sacubitril calcium adopts (R,E)-5-([1,1'-biphenyl]-4-yl)-4-((t-butyloxycarboryl)amino)-2-methyl-pentyl-2-olfine acid, and hydrogenation, esterification and acylation reactions are carried out, so that sacubitril calcium is obtained. The provided preparation method is simple to operate, low in cost and applicable to industrial production.

SACUBITRIL INTERMEDIATE AND PREPARATION METHOD THEREOF

The present invention relates to a sacubitril intermediate and a preparation method thereof. The sacubitril intermediate disclosed herein can be prepared by a deprotection reaction of a compound. In addition, the intermediate can be used as a raw material to synthesize sacubitril. The method disclosed herein has advantages of easily obtained raw materials, simple preparation process, low cost, environment friendly, and etc., which is very suitable for industrial production.

Method for preparing LCZ696 impurity reference substance

The invention provides a method for preparing an LCZ696 impurity reference substance. The method comprises the following steps: performing a reaction on (2R, 4S)-5-(biphenyl-4-yl)-4-[(t-butyloxycarboryl) amino]-2-methylpentanoic acid and thionyl chloride in ethanol so as to obtain a compound of formula I; performing a reaction on the compound of the formula I under a weak alkali condition so as to obtain a compound of formula II; performing heating reflux on succinic anhydride in isopropanol so as to obtain a compound of formula III; performing a reaction on the compound of the formula III with thionyl chloride so as to obtain a compound of formula IV; preparing the LCZ696 impurity reference substance of formula V from the compound of the formula II and the compound of the formula IV under catalysis of a strong alkali catalyst. By adopting the method provided by the invention, consumption of raw materials is reduced as a whole, the method is economic and environmental-friendly, different steps of reactions can be relatively easily implemented and controlled, meanwhile the amount of heavy metal catalysts is reduced and avoided, and the quality indexes of final products are improved.

A LCZ696 preparation method of drug impurity (by machine translation)

The present invention provides a LCZ696 preparation method of drug impurities, including: the (2 R, 4 S) - 5 - (biphenyl - 4 - yl) - 4 - [(uncle butoxy carbonyl) amino] - 2 - methyl valeric acid in chloro- medicinal preparation in the reaction with the organic alcohol, in order to get the product and succinic anhydride as a raw material, preparation (2 R, 4 S) - 5 - biphenyl - 4 - yl - 4 - (2, 5 - dicarbonyl - pyrrolidine - 1 - yl) - 2 - methyl pentanoate; make (2 R, 4 S) - 5 - biphenyl - 4 - yl - 4 - (2, 5 - dicarbonyl - pyrrolidine - 1 - yl) - 2 - methyl pentanoate hydrolyzed under acidic conditions, make (2 R, 4 S) - 5 - biphenyl - 4 - yl - 4 - (2, 5 - dicarbonyl - pyrrolidine - 1 - yl) - 2 - methyl valeric acid. The method of the invention the operation is simple, low cost, and is capable of LCZ696 pharmaceutical quality control to provide qualified reference substance. (by machine translation)

PROCESS FOR THE PREPARATION OF SACUBITRIL OR SALTS THEREOF

The present invention provides processes for the preparation of sacubitril or salts thereof. The present invention further provides intermediates of Formula IV, V and VI and their use for the preparation of sacubitril or salts thereof.

Preparation method and application of high-optical-purity biphenylalanine and derivative thereof

The invention relates to a preparation method and application of high-optical-purity biphenylalanine and a derivative thereof. The preparation method employs an acidic resolution reagent and controls the pH value of a reaction so as to prepare a target compound. According to the invention, raw materials are simple, easily available and cheap; the product obtained after resolution has high optical purity, so the problem of a final product with high optical purity is hard to prepare through refining in the prior art; and the preparation method is simple to operate, high in security, and low in the usage amount of wastewater and energy consumption, can overcome EHS problems in drug development, and is suitable for industrial large-scale production.

Sacubitril intermediate and preparation method thereof

The invention relates to a sacubitril intermediate and a preparation method thereof, the sacubitril intermediate is a compound shown as formula (04), and the sacubitril intermediate is prepared by deprotection reaction of a compound shown as formula (03). Further, the invention also provides the preparation method of the compound shown as the formula (04) as the intermediate. The method has the advantages of easy availability of raw materials, simple process, economy and environmental protection, and the like, and is very suitable for industrial production.

BIPHENYL-SUBSTITUED 4-AMINO-BUTYRIC ACID DERIVATIVES AND THEIR USE IN THE SYNTHESIS OF NEP INHIBITORS

The invention relates to a novel process, novel process steps and novel intermediates useful in the synthesis of pharmaceutically active compounds, in particular neutral endopeptidase (NEP) inhibitors and prodrugs thereof.

Sacubitril intermediate and preparation method of sacubitril intermediate and sacubitril

The invention discloses a sacubitril intermediate and a preparation method of the sacubitril intermediate and sacubitril, and belongs to the technical field of organic synthesis of drugs. On one hand, the invention discloses a novel compound-sacubitril intermediate compound B and a preparation method thereof, and on the other hand, the invention discloses a novel preparation method of the sacubitril. The sacubitril intermediate and the preparation method of the sacubitril intermediate and the sacubitril have the following advantages that the synthesizing route is short, the product can be prepared only through four steps of chemical reactions, and the steps of existing patent routes all exceed nine steps; the dicarbonyl compound is prepared through Reformasky condensation supplied by the method, and the cost is low; a first chiral center is introduced by fully utilizing a chiral compound L-(S)-ethyl lactate which is low in cost and easy to obtain in the natural world, and the cost is low; a second chiral center is constructed through a biological enzyme catalysis technique, the optical selectivity reaches up to 99.9%, the quality is good, and the cost is low. By means of the technological means, the total yield of the prepared sacubitril is increased, and the quality of the sacubitril is improved.